Are you a frequent visitor to retail drugstores? Then you must have come across at least one of the 8,240 drugstores operated by Walgreens Boots Alliance, Inc. (WBA - Analyst Report). This Illinois-based company is the first global pharmacy-led, health and wellbeing enterprise.
Currently, Walgreens has a Zacks Rank #3 (Hold) but that could change following its mixed third quarter fiscal 2015 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Walgreens’ adjusted earnings per share of $1.02 comfortably outpaced the Zacks Consensus Estimate of 87 cents.
Revenues: Walgreens posted revenues of $28.8 billion which missed the Zacks Consensus Estimate for revenues of $30.3 billion.
Key Stats : Revenue from the Retail Pharmacy USA division increased 5.3% to $20.4 billion, while the Retail Pharmacy International division delivered sales of $3.3 billion. On the other hand, the Pharmaceutical Wholesale division delivered sales of $5.7 billion. Moreover, Walgreens filled 226 million prescriptions (including immunizations) on a 30-day adjusted basis in the quarter, reflecting an increase of 3.8 % over third quarter of fiscal 2014.
Major Factors : Currently, Walgreens aims at improving its global business performance, reinvesting in the stores of the Retail Pharmacy USA division to improve the customer experience and expand retail margins and lastly restructuring its cost base, particularly in the U.S. Through these efforts, Walgreens is determined to become a leading innovative, pharmacy-led health care.
Stock Price : Following the earnings release, share prices did not show any movement in the pre-market trading session.
Get the latest research report on WBA - FREE
Update: See more detailed analysis here.
Comments
Log in or sign up to join the conversation.